Aerami Therapeutics to Present Data Supporting AER-901 Dosing Regimen at CHEST 2023
05 oct. 2023 08h00 HE
|
Aerami Therapeutics Inc
DURHAM, N.C., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Aerami Therapeutics (“Aerami”), a clinical stage biopharmaceutical company dedicated to breathing life into the treatment of serious and rare...
Aerami Therapeutics Announces Presentation of Phase 1 Clinical Trial Data for Lead Program AER-901 at the 2023 European Respiratory Society (ERS) International Congress
12 sept. 2023 09h48 HE
|
Aerami Therapeutics Inc
DURHAM, N.C., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Aerami Therapeutics (“Aerami”), a clinical stage biopharmaceutical company dedicated to breathing life into the treatment of serious and rare...
Aerami Therapeutics Appoints Joshua Ziel as COO and Interim CEO and Expands Management Team as Lead Asset AER-901 (inhaled imatinib) Advances Toward Phase 2 in Pulmonary Hypertension
01 juin 2023 08h00 HE
|
Aerami Therapeutics Inc
Joshua Ziel, PhD, appointed as Chief Operating Officer and interim Chief Executive Officer Gary Burgess, MD, appointed as Chief Medical OfficerSarah Fritchley, PhD, appointed as Senior Vice President,...
Aerami Therapeutics Announces Pharmacokinetic Data Demonstrating the Potential of AER-901 (Inhaled Imatinib) to Achieve Therapeutic Levels at Low Inhaled Doses for Treatment of Pulmonary Hypertension
24 mai 2023 08h58 HE
|
Aerami Therapeutics Inc
DURHAM, N.C., May 24, 2023 (GLOBE NEWSWIRE) -- Aerami Therapeutics (“Aerami”), a clinical stage biopharmaceutical company dedicated to breathing life into the treatment of serious and rare...
Aerami Therapeutics to Present Pharmacokinetic Data Supporting AER-901 (Inhaled Imatinib) for Pulmonary Hypertension at the 2023 American Thoracic Society (ATS) International Conference
11 mai 2023 08h00 HE
|
Aerami Therapeutics Inc
DURHAM, N.C., May 11, 2023 (GLOBE NEWSWIRE) -- Aerami Therapeutics (“Aerami”), a clinical stage biopharmaceutical company dedicated to breathing life into the treatment of serious and rare...
Aerami Therapeutics Mourns the Sudden Loss of Chief Executive Officer Lisa Yañez
05 mai 2023 07h00 HE
|
Aerami Therapeutics Inc
DURHAM, N.C., May 05, 2023 (GLOBE NEWSWIRE) -- It is with deep sadness that Aerami Therapeutics (“Aerami”) today announces that our dear friend, fierce patient advocate, dedicated mentor, and CEO,...
Aerami Therapeutics to Host Virtual Investor Day with Leading Experts in Pulmonary Hypertension as AER-901 (Inhaled Imatinib) Advances Toward Phase 2
03 avr. 2023 09h00 HE
|
Aerami Therapeutics Inc
DURHAM, N.C., April 03, 2023 (GLOBE NEWSWIRE) -- Aerami Therapeutics (“Aerami”), a clinical stage biopharmaceutical company dedicated to breathing life into the treatment of serious and rare...
Aerami Therapeutics Announces Expansion of the AER-901 (inhaled imatinib) Development Program in Pulmonary Hypertension Supported by Phase 1 Clinical Trial Data and Continued Progress
23 févr. 2023 09h00 HE
|
Aerami Therapeutics Inc
Expansion of the AER-901 development program to include pulmonary hypertension associated with interstitial lung disease (PH-ILD) builds on the company’s existing program in pulmonary arterial...
Aerami Therapeutics to Present at Biotech Showcase™ 2023 during the 41st Annual J.P. Morgan Healthcare Conference Week
05 janv. 2023 09h00 HE
|
Aerami Therapeutics Inc
DURHAM, N.C., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Aerami Therapeutics (“Aerami”), a clinical stage biopharmaceutical company dedicated to breathing life into the treatment of serious cardiopulmonary...
Aerami Therapeutics Announces Completion of Dosing in Phase 1 Trial of AER-901 (inhaled imatinib), a Critical Milestone Toward the Planned Initiation of a Phase 2 Trial in Pulmonary Arterial Hypertension (PAH) During the First Half of 2023
21 déc. 2022 08h01 HE
|
Aerami Therapeutics Inc
AER-901 (inhaled imatinib), a potential reverse-remodeling therapy, is being developed to address unmet need for PAH treatments that target pulmonary vascular remodeling while supporting ease-of-use...